======= NAA50 =======
== Gene Information ==
* **Official Symbol**: N/AA50
* **Official Name**: N-alpha-acetyltransferase 50, NatE catalytic subunit
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=80218|80218]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9GZZ1|Q9GZZ1]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=NAA50&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20NAA50|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/610834|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: N-alpha-acetyltransferase that acetylates the N-terminus of proteins that retain their initiating methionine (PubMed:19744929, PubMed:22311970, PubMed:21900231, PubMed:27484799). Has a broad substrate specificity: able to acetylate the initiator methionine of most peptides, except for those with a proline in second position (PubMed:27484799). Also displays N-epsilon-acetyltransferase activity by mediating acetylation of the side chain of specific lysines on proteins (PubMed:19744929). Autoacetylates in vivo (PubMed:19744929). The relevance of N-epsilon-acetyltransferase activity is however unclear: able to acetylate H4 in vitro, but this result has not been confirmed in vivo (PubMed:19744929). Component of a N-alpha- acetyltransferase complex containing NAA10 and NAA15, but NAA50 does not influence the acetyltransferase activity of NAA10: this multiprotein complex probably constitutes the major contributor for N-terminal acetylation at the ribosome exit tunnel, with NAA10 acetylating all amino termini that are devoid of methionine and NAA50 acetylating other peptides (PubMed:16507339, PubMed:27484799). Required for sister chromatid cohesion during mitosis by promoting binding of CDCA5/sororin to cohesin: may act by counteracting the function of NAA10 (PubMed:17502424, PubMed:27422821). {ECO:0000269|PubMed:16507339, ECO:0000269|PubMed:17502424, ECO:0000269|PubMed:19744929, ECO:0000269|PubMed:21900231, ECO:0000269|PubMed:22311970, ECO:0000269|PubMed:27422821, ECO:0000269|PubMed:27484799}.
|Acetyltransf 1|
|peptidyl-lysine acetyltransferase activity|
|establishment of mitotic sister chromatid cohesion|
|mitotic sister chromatid cohesion, centromeric|
|NatA complex|
|establishment of sister chromatid cohesion|
|centromeric sister chromatid cohesion|
|N-acetyltransferase activity|
|H4 histone acetyltransferase activity|
|peptide alpha-N-acetyltransferase activity|
|mitotic sister chromatid cohesion|
|N-terminal protein amino acid acetylation|
|N-terminal protein amino acid modification|
|sister chromatid cohesion|
|histone H4 acetylation|
|mitotic sister chromatid segregation|
|histone acetylation|
|internal peptidyl-lysine acetylation|
|peptidyl-lysine acetylation|
|internal protein amino acid acetylation|
|sister chromatid segregation|
|protein acetylation|
|mitotic nuclear division|
|protein acylation|
|nuclear chromosome segregation|
|protein maturation|
|chromosome segregation|
|nuclear division|
|organelle fission|
|peptidyl-lysine modification|
|histone modification|
|covalent chromatin modification|
|mitotic cell cycle process|
|mitotic cell cycle|
|chromatin organization|
|peptidyl-amino acid modification|
|cell cycle process|
|chromosome organization|
|cell cycle|
|gene expression|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp80|RO-3307 4.7μM R02 exp80]]|-2.06|
|[[:results:exp231|Epothilone-B 0.0015μM R05 exp231]]|-1.92|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|-1.84|
|[[:results:exp532|TIC10 10μM R08 exp532]]|-1.74|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|-1.7|
|[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|1.7|
|[[:results:exp504|MK2206 4μM R08 exp504]]|1.76|
|[[:results:exp421|VHL-ligand-1 20μM R07 exp421]]|1.78|
|[[:results:exp341|BRD2 inhibitor II 20μM R07 exp341]]|1.8|
|[[:results:exp399|Salubrinal 20μM R07 exp399]]|1.82|
|[[:results:exp429|Rapamycin 0.001μM R08 exp429]]|1.86|
|[[:results:exp316|Geldanamycin 0.015 to 0.025μM on day4 R07 exp316]]|1.93|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|1.93|
|[[:results:exp420|Tunicamycin 0.04 to 0.125μM on day4 R07 exp420]]|1.95|
|[[:results:exp308|Rapamycin 2μM plus FK-506 5μM R07 exp308]]|1.97|
|[[:results:exp496|Lead acetate 990μM R08 exp496]]|2.15|
|[[:results:exp334|All-trans-Retinoic-Acid 40μM R07 exp334]]|2.38|
|[[:results:exp418|Tunicamycin 0.04μM R07 exp418]]|2.58|
^Gene^Correlation^
|[[:human genes:t:tsc2|TSC2]]|0.436|
|[[:human genes:p:pds5b|PDS5B]]|0.435|
Global Fraction of Cell Lines Where Essential: 671/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|25/28|
|blood|26/28|
|bone|23/25|
|breast|31/33|
|central nervous system|56/56|
|cervix|4/4|
|colorectal|14/17|
|esophagus|13/13|
|fibroblast|1/1|
|gastric|13/15|
|kidney|20/21|
|liver|19/20|
|lung|72/75|
|lymphocyte|14/14|
|ovary|22/26|
|pancreas|22/24|
|peripheral nervous system|16/16|
|plasma cell|14/15|
|prostate|1/1|
|skin|20/24|
|soft tissue|6/7|
|thyroid|2/2|
|upper aerodigestive|17/22|
|urinary tract|25/29|
|uterus|5/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 1749
* **Expression level (log2 read counts)**: 7.7
{{:chemogenomics:nalm6 dist.png?nolink |}}